<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02241590</url>
  </required_header>
  <id_info>
    <org_study_id>SGHLC20140818001</org_study_id>
    <nct_id>NCT02241590</nct_id>
  </id_info>
  <brief_title>Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Liver Cirrhosis Patients Due to Hepatitis B Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ShuGuang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Ruikang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hubei Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huai'an No. 4 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Third People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wenzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jingmen No.1 People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Shandong Univercity of TCM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Ninth Hospital of Nanchang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The People's Hospital of Ningxia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fifth Hospital of Shijiazhuang City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fifth People's Hospital of Suzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fifth People’s Hospital of Anyang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ShuGuang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver Cirrhosis is a common pathological consequence of chronic liver disease. Hepatitis B
      Virus (HBV) is one of most etiologies of liver cirrhosis in China. The effective inhibition
      of HBV can partially stop or reverse liver fibrosis in patients with chronic Hepatitis and
      liver cirrhosis due to HBV, and the anti-fibrotic strategy focusing on the regulation of
      hepatic extracellular matrix is still required and hopefully improve the efficacy of
      anti-virals for liver fibrotic patients with HBV, especially is necessary for in the patients
      with advance fibrosis stage ie. liver cirrhosis. Fuzheng Huayu has been found to enhance the
      degradation of collagens in fibrotic liver and have a good action against liver fibrosis in
      patients with chronic hepatitis B. However, there are no high quality clinical evidences
      which can demonstrate if the combination of anti-viral and anti-fibrotic therapy can improve
      the reversion of liver cirrhosis due to HBV.

      The primary objective of this study is to establish the safety and efficacy of the
      combination of Entecavir and Fuzheng Huayu for the reversion of liver fibrosis in patients
      with liver cirrhosis due to HBV.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of liver fibrosis</measure>
    <time_frame>48 weeks</time_frame>
    <description>The collagen of liver tissue from 48 week post-treatment patients was stained. 3 pathologists read the slides independently and score the slides with Ishak system. If the Ishak score decrease 1 or more than 1 score, then it is recorded as reversion.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Liver Cirrhosis Due to Hepatitis B Virus</condition>
  <arm_group>
    <arm_group_label>Entecavir + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablet with Entrcavir+ Tablet with starch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entecavir + Fuzheng Huayu Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet with Entrcavir+ Tablet with Fuzheng Huayu</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir + Placebo</intervention_name>
    <description>The subjects will be taking 1 Entecavir tablet per day and 4 Placebo tablets three times a day for 48 weeks.</description>
    <arm_group_label>Entecavir + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir + Fuzheng Huayu Tablet</intervention_name>
    <description>The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 48 weeks.</description>
    <arm_group_label>Entecavir + Fuzheng Huayu Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  More than 6 months history of serum positive HBsAg

          -  Positive HBV-DNA

          -  Age 18-60

          -  Ishak fibrosis score of the biopsy within 6 months ≥5, no anti-virus or anti-fibrosis
             drug was taken within 6 months.

          -  Child-Pugh&lt;7 (Stage A)

          -  The patient or the patient's guardian agrees to participate the random controlled
             trial and sign the Informed Consent Form.

        Exclusion Criteria:

          -  Primary Lamivudine, Adefovir dipivoxil and Entecavir resistance

          -  Decompensated liver cirrhosis

          -  Liver cancer

          -  Liver histology conform to other chronic liver disease cause (exclude fatty liver)

          -  Non-HBV avihepadnavirus infected acute and chronic hepatitis, autoimmune hepatitis,
             primary biliary cirrhosis, primary sclerosing cholangitis, inherited metabolic liver
             disease, drug or toxic hepatitis, Alcoholic liver disease.

          -  Have psychiatric history or uncontrollable epilepsy patient.

          -  Uncontrollable diabetic patient

          -  History of Hemoglobin disease (such as Alpha globin generation barrier anemia, Sickle
             cell deficiency, Spherocytosis) or Hemolytic anemia patients caused by other reasons
             like autoimmunity.

          -  Severe background disease like chronic respiratory failure, circulatory failure,
             kidney failure etc.

          -  In situ organ transplantation (such as liver, kidney, lung and heart) or bone marrow
             transplantation and stem cell transplantation.

          -  Immunocompromised patients: such as HIV infection or take immunosuppressor or
             glucocorticoid (such as cyclosporin, azathioprine, adrenocortical hormone) within 3
             months or chemotherapy drugs (such as cyclophosphamide, ammonia and cancer
             chemotherapy) and radioactive therapy.

          -  Gestation or lactation period women and women who plan to get pregnant during the
             study period.

          -  Patient who are allergy to the experimental drug.

          -  Using history of anti-viral or anti-fibrosis drug within 6 months.

          -  Patients who are participating other trials.

          -  Other situation where PI thinks the patient should be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chenghai Liu, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ShuGuang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chenghai Liu, PhD</last_name>
    <phone>8621-20256521</phone>
    <email>chenghailiu@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangxi Ruikang Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Fifth Hospital of Shijiazhuang</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Fifth People's Hospital of Anyang</name>
      <address>
        <city>Anyang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jingmen No.1 People's Hospital</name>
      <address>
        <city>Jingmen</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hubei Hospital of TCM</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Hunan University of TCM</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huai'an No. 4 People's Hospital</name>
      <address>
        <city>Huai'an</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Fifth People's Hospital of Suzhou</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ninth Hospital of Nanchang</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ningxia People's Hospital</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Shandong Univercity of TCM</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wenzhou Central Hospital</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Ditan Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Youan Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guang'anmen Hospital, China Academy of Chinese Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ShuGuang Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>201203</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhimin Zhao, PhD</last_name>
      <phone>+8615800581663</phone>
      <email>kilorair@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shenzhen Third People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2014</study_first_submitted>
  <study_first_submitted_qc>September 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2014</study_first_posted>
  <last_update_submitted>November 29, 2015</last_update_submitted>
  <last_update_submitted_qc>November 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ShuGuang Hospital</investigator_affiliation>
    <investigator_full_name>Liu Chenghai</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

